Keywords: CTLA, cytotoxic T-lymphocyte–associated protein 4; FDA, US Food and Drug Administration; IFN-α, interferon alfa; MAPK, mitogen-activated protein kinase; PD-1, programmed death-1; SOTRs, solid organ transplant recipients; immunosuppression; metastatic melanoma; organ transplant; systemic therapy.